19Oct

Demystify Chromogenic Factor VIII Testing’

For laboratories wishing to accurately quantify Factor VIII activity, there is now a ready-to-use Chromogenic Factor VIII Assay. The CRYOcheck™ assay is designed for ease of use and to minimise reagent waste. The assay is intended to identify Factor VIII deficiency and aid in the management of haemophilia A.

Available in the UK exclusively from Alpha Laboratories, the new kit developed by Precision BioLogic offers a validated protocol.

CRYOcheck Chromogenic Factor VIII is the only chromogenic assay offered in a frozen format.  The vials are simply thawed in a standard water bath, loaded onto an automated coagulation analyser, and they ready to go!  With only four separate components, provided in convenient colour coded vials, running the assay is very straight forward. 

The CRYOcheck Chromogenic Factor VIII assay is suitable for both high and low volumes of testing. It can be scaled up in the lab for high volume testing, and the ability to store unused reagents refrigerated for up to 5 days, or frozen for up to 1 month, makes the kit perfect for low volume testing too. The kit offers total flexibility in Factor VIII activity testing.

The Assay will save you time, improve your workflow and eliminate reconstitution errors.  The CRYOcheck Chromogenic Factor VIII Assay provides unsurpassed assurance in results.

Please visit www.alphalabs.co.uk/cccf08 for further information or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk   

Related

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and ...

Read More >

Cytox appoints new CCO

Oxford and Manchester, UK – Cytox, a precision medicine company focused on developing solutions to ...

Read More >

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

Specific, intermediate glycemic control marker for diabetes at EKF’s Booth #2952 at AACC 2019 Clini...

Read More >

OGT pushes forward hybridisation-based targeted sequencing

Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made se...

Read More >

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Belgium, 16 May 2017 – Multiplicom, an Agilent Technologies Company, announced today the extended C...

Read More >

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch ...

Read More >